摘要
泛素化特异性蛋白酶22(USP22)是一种去泛素化酶,其通过去除蛋白底物的泛素连接,影响c-Myc、Bmi-1、FBP-1等靶基因的表达,从而调控细胞周期进展、细胞生长分化等一系列生物学行为,可能导致肿瘤的发生。目前已发现USP22在甲状腺癌、喉癌、口腔鳞癌等多种肿瘤组织细胞中高表达,且与恶性肿瘤的分期、预后密切相关,是近年来被广泛研究的肿瘤标记物,对USP22生理作用机制的探讨已成为目前肿瘤学方面的研究热点。USP22可能作为抗肿瘤治疗新的作用靶点,但相关药物仍需进一步研究。
Ubiquitin specific protease 22(USP22) is a novel deubiquitinating enzyme which cleaves ubiquitin(Ub) from Ub-conjugated protein substrates, affects c-Myc, Bmi-1, FBP-1 and other target genes, and regulates cell cycle progression, cell proliferation and differentiation. It has been reported to be involved in tumor progression. Overexpression of USP22 gene has been found in several tumors such as thyroid carcinoma, laryngeal carcinoma and oral squamous cell carcinoma, which is associated with the stage and prognosis of tumors. This biomarker plays an important role in the research of pathogenesis and therapy of tumor. The study of its function, biochemical mechanism and connection with tumor is a research highlight nowadays. USP22 may be served as a new therapeutic target of tumor, but relevant drugs need to be further researched.
出处
《海南医学》
CAS
2016年第2期257-261,共5页
Hainan Medical Journal
关键词
泛素特异性蛋白酶22
肿瘤
细胞周期
预后
Ubiquitin specific protease 22(USP22)
Tumor
Cell cycle
Prognosis
